PI
Prof. Reinhard Dummer
Adjuvant, Melanom Stadium III-IV
Relatlimab + Nivolumab
vs
Nivolumab
BMSCA224-098
(RELATIVITY 098)
NCT05002569
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
Prof. Reinhard Dummer